Drug Type CAR-NK |
Synonyms- |
Target |
Action inhibitors |
Mechanism T-cell surface glycoprotein CD5 inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Lymphocytic Leukemia | Preclinical | United States | 11 Apr 2022 | |
Chronic Lymphocytic Leukemia | Preclinical | United States | 11 Apr 2022 | |
T-Cell Lymphoma | Preclinical | United States | 11 Apr 2022 | |
T-Cell Lymphoma | Preclinical | United States | 11 Apr 2022 |